Sucampo Pharmaceuticals Provides Update On Anticipated Arbitration Decision

Please replace the release with the following corrected version due to multiple revisions

The corrected release reads:

SUCAMPO PHARMACEUTICALS PROVIDES UPDATE ON ANTICIPATED ARBITRATION DECISION

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that the International Court of Arbitration, International Chamber of Commerce (ICC) has notified the Company of a change in the anticipated date of the decision related to the Company’s demand for arbitration under the applicable provisions of the Collaboration and License Agreement with Takeda Pharmaceutical Company Limited, or Takeda. The ICC has extended the date from June 29, 2012 to July 31, 2012.

Sucampo is eager to receive the ICC’s decision as quickly as possible, and we continue our substantial planning in anticipation of a favorable award. Through these efforts, we look forward to increasing patient and healthcare provider access to AMITIZA ® in the event of a favorable outcome.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com.

Sucampo Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.

If you liked this article you might like

Biotech Premarket Movers: Sucampo, Intellia, Cytokinetics

Big-Cap Tech Names, Biotechs, Oils Lifting Market

The Pockets of Speculative Action Have Dried Up

Shark Bites: Entry Points Are Scarce

Weak On High Volume: Sucampo Pharmaceuticals (SCMP)